Luspatercept and imetelstat for myelodysplastic syndrome: updates from ASH 2025 annual meeting
Abstract Luspatercept, an erythroid maturation agent, and imetelstat, a first-in-class telomerase inhibitor, have expanded the therapeutic landscape for patients with myelodysplastic neoplasms (MDS). Recent data presented at the 2025 American Society of Hematology (ASH) Annual Meeting further clarif...
-д хадгалсан:
| Үндсэн зохиолчид: | , , |
|---|---|
| Формат: | Artigo |
| Хэл сонгох: | Inglês |
| Хэвлэсэн: |
BMC
2026-06-01
|
| Цуврал: | Journal of Hematology & Oncology |
| Нөхцлүүд: | |
| Онлайн хандалт: | https://doi.org/10.1186/s13045-026-01815-5 |
| Шошгууд: |
Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!
|